Data and statistics

Biotechnology

Biotechnology enables advances in health, agriculture, environment and industry. Medical biotechnology is the major application of biotechnology in Australia, currently. However, the OECD predicts that by 2030, biotechnology may have the greatest impact in the primary production and industry sectors.

The department estimates that there are around 480 biotechnology active companies across major application areas (medical, agricultural, environmental and industrial) in Australia.

The majority of these companies are research-intensive small to medium enterprises operating in the start-up or expansion phase. These include spin-outs from universities and other publicly funded or not-for-profit research organisations. CSL is Australia’s largest biotechnology company, which develops and manufactures blood plasma products, cell culture media, vaccines and anti-venoms.

Biotechnology is not a defined sector under the Australian and New Zealand Standard Industry Classification. As such, the majority of available industry data is drawn from publicly listed companies.

Australian biotechnology at a glance, 2012-13 (US$ millions)
  2013 2012 % change
Public company data
Revenues 5,316 4,998 6%
R&D expense 644 594 8%
Net income (loss) 962 770 25%
Market capitalisation 38,111 33,192 15%
Number of employees 12,380 11,010 12%
Number of public companies 50 52 -4%

Source: Ernst & Young - Beyond Borders, Biotechnology Industry Report 2014
Note: Figures are assumed to be based on global revenues, expenditures and employment>br /> Note*: Reported employment for 33 public companies in FY13 indicates around 2,395 employees in Australia

Quarterly performance – June 2014
Market capitalisation (A$m)
31-Dec-13 31-Mar-14 30-Jun-14 % Change (Dec-Mar) % Change (Mar-Jun)
Pharma/Biotech 40,057 40,769 37,782 1.8% -7.3%
Pharma/Biotech ex CSL 6,608 7,106 5,976 7.5% -15.9%

Source: PWC BioForum Edition 48, August 2014
Note: Based on the PWC Pharma/biotech Index

Quarterly summary – June 2014
MCap (A$m) Companies with share price gains Proportion of subsector up Companies with share price losses Proportion of subsector down Companies with share price flat Proportion of subsector flat Total number of companies
Pharma/
Biotech
37,782 7 13% 46 87% - 0% 53
Pharma/
Biotech ex CSL
5,976 7 13% 45 87% - 0% 52

Source: PWC BioForum Edition 48, August 2014
Note: Based on the PWC Pharma/biotech Index

Market capitalisation over A$200 million at 30 June 2014
ASX Code Company Name Closing Market Capitalisation (A$m)
CSL CSL Limited 31,807
MSB Mesoblast Limited 1,474
SRX Sirtex Medical 948
MYX Mayne Pharma Group Limited 502
BNO Bionomics 240

Source: PWC BioForum Edition 48, August 2014
Note: Figures may vary due to rounding

Business Expenditure on Research and Development

According to the Australian Bereau of Statistics, in 2010-11, business expenditure on R&D by biotechnology fields of research was A$184 million, or around 1 per cent of total business expenditure on R&D in Australia in 2010-11. Of this, medical biotechnology accounted for around 72 per cent or $133 million; agricultural biotech 12 per cent or $22 million; environmental biotech 9 per cent or $17 million; and industrial biotech around 7 per cent or $12 million. Data for 2010-11 was the last available.

Inquiries

Biotechnology

Market capitalisation of selected biotechnology companies listed on the Australian Securities Exchange

Market capitalisation of selected biotechnology companies listed on the Australian Securities Exchange

Source: Biotechnology Business Indicators (BBI), Department of Industry, 2012
Text description for Market capitalisation of selected biotechnology companies listed on the Australian Securities Exchange

Revenues for public biotechnology companies in Australia

Revenues for public biotechnology companies in Australia

Source: Ernst & Young, Beyond Borders, Global Biotechnology Reports, 2005 to 2012
Notes: Figures represent selected public companies in Australia. Numbers may vary between year of publication
Text description for Revenues for public biotechnology companies in Australia

Employment by Public Biotechnology Companies in Australia

Employment by Public Biotechnology Companies in Australia

Source: Ernst & Young, Beyond Borders, Global Biotechnology Reports, 2005 to 2012
Notes: Figures represent selected public companies in Australia. Numbers may vary between year of publication.
Text description for Employment by Public Biotechnology Companies in Australia

Business expenditure on research and development, by biotechnology fields of research, 2007 - 2011

Business expenditure on research and development, by biotechnology fields of research, 2007 - 2011

Source: ABS cat. No. 8104.0 (2010-11)
Text description for Business expenditure on research and development, by biotechnology fields of research, 2007 - 2011

Growth in business expenditure on biotechnology R&D versus total R&D in Australia, 2007-08 to 2010-11

Growth in business expenditure on biotechnology R&D versus total R&D in Australia, 2007-08 to 2010-11

Source: ABS cat. no. 8104.0 (2010-11)
Note: BERD stands for Business Expenditure on Research and Development
Text description for Growth in business expenditure on biotechnology R&D versus total R&D in Australia, 2007-08 to 2010-11

Comparison of Business (BERD), Government (GovERD) and Higher Education (HERD) Expenditure on R&D, by biotechnology fields of research, 2009-10

Comparison of Business (BERD), Government (GovERD) and Higher Education (HERD) Expenditure on R&D, by biotechnology fields of research, 2009-10

Source: Based on ABS 2011, customised report
Note*: HERD reference period calendar year 2008. GovERD reference period 2008-09.
Text description for Comparison of Business, Government and Higher education Expenditure on R&D, by biotechnology fields of research, 2009-10

Venture capital and later stage private equity, by activity, 2007 - 2011

Venture capital and later stage private equity, by activity, 2007 - 2011

Source: ABS cat. No. 5678.0 (2010-11)
Text description for Venture capital and later stage private equity, by activity, 2007 - 2011

Nanotechnoogy

Business expenditure on nanotechnology research and development, 2007 – 2011

Business expenditure on nanotechnology research and development, 2007 – 2011 

Source: ABS cat. No. 8104.0 (2010-11)
Text description for Business expenditure on nanotechnology research and development, 2007-2011

Comparison of Business (BERD), Government (GovERD) and Higher Education (HERD) Expenditure on nanotechnology R&D, 2008 - 2011

Comparison of Business (BERD), Government (GovERD) and Higher Education (HERD) Expenditure on nanotechnology R&D, 2008 - 2011

Source: Based on ABS 2011 & 2012, Customised reports
Note*: HERD reference period calendar year 2008 and 2010. GovERD reference period 2008-09
Text description for Comparison of Business (BERD), Government (GovERD) and Higher Education (HERD) Expenditure on nanotechnology R&D, 2008 - 2011

Share this Page